Understanding the FDA Warning on Cetirizine/Levocetirizine
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Understanding the FDA Warning on Cetirizine/Levocetirizine
-
Lu par :
-
De :
À propos de cette écoute
Welcome to a special episode of AllergyTalk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma & Immunology!
On May 16, 2025, the FDA issued an alert regarding a rare but serious side effect of severe pruritus after discontinuing long-term use of cetirizine and levocetirizine. In this episode, we’ll discuss the background of this important announcement and what it means for our patients!
We are joined by Michael S. Blaiss, MD, clinical professor of pediatrics at the Medical College of Georgia and past-president and former Executive Medical Director of the American College of Allergy, Asthma, and Immunology. He has been a consultant for multiple companies manufacturing second generation antihistamines.
Resources:
FDA Drug Safety Communication on Cetirizine and Levocetirizine
ACAAI Advice on Speaking Points Regarding FDA Alert
Previous articles describing this side effect:
Unbearable Pruritus After Withdrawal of (Levo)cetirizine.
Pruritus after discontinuation of cetirizine.
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
